FDA approves Arcutis’ Zorvye (roflumilast) cream 0.15% for the treatment of atopic dermatitis in adults and children down to 6 years of age

Arcutis Biotherapeutics

9 July 2024 - Commercial product expected to be available by the end of July.

Arcutis Biotherapeutics today announced the US FDA has approved the supplemental new drug application for Zorvye (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and paediatric patients 6 years of age and older.

Read Arcutis Biotherapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US